Skip to main content

Table 3 Total and incremental results (bedaquiline plus BR versus BR) in the high burden countries analyzed

From: Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries

  Estonia Russia South Africa Peru China Philippines India
Cohort
 Populationa, cases (n) 38 6,537 6,494 564 826 11 20,763
Estimated Total DALYs, avoided
 Bedaquiline + BR 438.41 72,824.26 78,816.95 8,318.51 7,329.94 152.50 299,598.12
 BR only 554.29 90,479.07 96,530.04 10,475.26 9,792.45 177.64 384,990.40
Estimated DALYs per patient, avoided
 Bedaquiline + BR 11.54 11.14 12.14 14.75 8.87 13.86 14.43
 BR only 14.59 13.84 14.86 18.57 11.86 16.15 18.54
 Incremental change in DALYs (bedaquiline + BR vs. BR) (%, relative to bedaquiline) -20.90 -19.51 -18.35 -20.59 -25.15 -14.16 -22.18
Patients with successful outcomes (%)
 Bedaquiline + BR 40.66 38.67 36.50 40.09 47.25 28.69 42.76
 BR only 26.29 24.83 23.55 25.88 31.16 17.85 27.97
 Incremental change in successful outcomes (bedaquiline + BR vs. BR) (%, relative to bedaquiline) +54.67 +55.78 +55.02 +54.87 +51.62 +60.78 +52.87
Number of cases of acquired resistance
 Bedaquiline + BR 2.16 349.72 28.20 31.88 52.90 0.50 1,274.00
 BR only 3.16 512.37 47.58 46.63 77.04 0.73 1,862.89
 Incremental change in acquired resistance (bedaquiline + BR vs. BR) (%, relative to bedaquiline) -31.59 -31.75 -40.8 -31.62 -31.34 -32.22 -31.61
  1. BR background regimen, DALY disability-adjusted life years
  2. aPopulation cohort: Russia, China, Philippines: New lab-confirmed MDR-TB cases in 2012 [31]; South Africa: Total number of patients started on MDR-TB treatment in 2012 [31]; Estonia, Peru: laboratory-confirmed MDR-TB cases in 2012 [31]; India: Total number of patients started on MDR-TB treatment in 2013 [2]